Sage Therapeutics Inc. (SAGE) Is Surging On Phase 2 Results For SAGE-547

Sage Therapeutics Inc. (SAGE) announced Tuesday morning that its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression achieved the primary endpoint of a significant reduction in the HAM-D score compared to placebo at 60 hours.

from RTT - Hot Stocks http://ift.tt/29TN7FV
via IFTTT